Post
of 161,753
So 17.9% survival rate for MTNBC. According the a search;
“Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of cancer with a lower survival rate compared to other breast cancer subtypes, though treatment options are evolving.
Survival Rates (5-Year)
Distant/Metastatic Stage: According to the American Cancer Society, the 5-year relative survival rate for distant (metastatic) TNBC is approximately 15%.
Real-World Data: Some studies indicate that the 5-year overall survival rate for mTNBC can range from 4% to 20%, with some data highlighting a rate of around 11%.
Survival Times: The median overall survival (OS) for mTNBC is generally reported between 11 and 15.5 months.
PubMed Central (PMC) (.gov)
PubMed Central (PMC) (.gov)”
So 17.9% does appear to be an improvement. Enough of an improvement to get the attention of a BP partner or the FDA?
That’s the billion dollar question.
“Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of cancer with a lower survival rate compared to other breast cancer subtypes, though treatment options are evolving.
Survival Rates (5-Year)
Distant/Metastatic Stage: According to the American Cancer Society, the 5-year relative survival rate for distant (metastatic) TNBC is approximately 15%.
Real-World Data: Some studies indicate that the 5-year overall survival rate for mTNBC can range from 4% to 20%, with some data highlighting a rate of around 11%.
Survival Times: The median overall survival (OS) for mTNBC is generally reported between 11 and 15.5 months.
PubMed Central (PMC) (.gov)
PubMed Central (PMC) (.gov)”
So 17.9% does appear to be an improvement. Enough of an improvement to get the attention of a BP partner or the FDA?
That’s the billion dollar question.
3